Standard Keytruda Dosage for Adults
Keytruda (pembrolizumab) is given as an intravenous infusion over 30 minutes every 3 or 6 weeks, depending on the dose and indication. The standard adult dose is 200 mg every 3 weeks or 400 mg every 6 weeks. Treatment continues until disease progression, unacceptable toxicity, or up to 2 years for certain adjuvant settings.[1][2]
Dosing varies by cancer type:
- Non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma, or classical Hodgkin lymphoma: 200 mg every 3 weeks or 400 mg every 6 weeks.
- Melanoma or microsatellite instability-high (MSI-H) cancers: Same as above.
- Triple-negative breast cancer or endometrial carcinoma: Often combined with chemotherapy at 200 mg every 3 weeks.
No dose adjustments for mild to moderate kidney or liver impairment, but hold or discontinue for severe cases or immune-related adverse events.[1]
Dosage for Children
Pediatric patients (under 30 kg body weight) receive 4 mg/kg every 3 weeks or 8 mg/kg every 6 weeks, up to a maximum of 200 mg or 400 mg, respectively. For patients 30 kg or more, use adult dosing. Approved for specific pediatric indications like MSI-H solid tumors or classical Hodgkin lymphoma.[1][2]
How Keytruda Is Administered
Infuse over 30 minutes through an IV line with a sterile, low-protein-binding 0.2-micron filter. Premedication isn't required, but monitor for infusion reactions. Do not administer as an IV push or bolus.[1]
Dose Adjustments and Management
| Scenario | Action |
|----------|--------|
| Mild immune-related adverse events (irAEs) | Withhold Keytruda; resume if improves to grade 1 or less. |
| Moderate irAEs | Withhold and start corticosteroids; permanent discontinue if no improvement. |
| Severe or life-threatening irAEs (e.g., pneumonitis, colitis) | Permanently discontinue. |
| Renal/hepatic impairment | No adjustment for mild/moderate; assess for moderate/severe. |
Follow guidelines from the manufacturer for rechallenge after resolution.[1][2]
Common Dosage Questions from Patients
Patients often ask about missed doses—administer as soon as possible, then resume schedule. Cost per dose is around $10,000-$12,000 (U.S. list price), but financial assistance programs exist. Long-term use up to 2 years is common in responders.[3]
Why Doses Differ by Indication
The 400 mg every 6 weeks option matches the 200 mg every 3 weeks exposure (AUC), offering scheduling flexibility without changing efficacy in trials like KEYNOTE-024 for NSCLC.[1][2]
Sources:
[1] Keytruda Prescribing Information (Merck)
[2] FDA Label for Pembrolizumab
[3] Drugs.com Keytruda Dosage Guide